clinical trial · NCT03492580
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen Research & Development, LLC·—·completed·n = 714,582
Diabetes Mellitus, Type 2Cardiovascular DiseasesCanagliflozinEmpagliflozinDapagliflozinDipeptidyl Peptidase-4 (DPP-4) InhibitorsGlucagon-like Peptide-1 (GLP-1) AgonistAnti-hyperglycemic Agents (AHA)Thiazolidinediones (TZD)Sulfonylureas (SU)
brief summary
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed and reported in this study.
started
Feb 22, 2018
primary completion
Apr 6, 2018
completion
Jun 25, 2018
last updated
Jun 25, 2025
official title
Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol